Replimune Gets Third Try at FDA Approval After Makary Departure

Date:




Experimental melanoma drug was rejected twice because the Food and Drug Administration questioned its study design.



Source link

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related

Opinion | Mamdani Wants to Deliver Amazon to the Teamsters

New York City may ban subcontracting delivery workers to...

Basketball HOF class of 2026 honors women’s hoops, NBA icons

Aug 15, 2026, 10:11 PM ETSPRINGFIELD, Mass. -- Candace...

Hawaii braces for impact from Lala

IE 11 is not supported. For an optimal experience...

Haaland and Hull make their points in Gubernatorial race

Haaland and Hull make their points in Gubernatorial raceDeb...